Core Viewpoint - Israel has removed Iranian Foreign Minister Amir-Abdollahian and Iranian Parliament Speaker Ghalibaf from its assassination list following a request from Pakistan to the U.S. [1] Group 1 - Israeli authorities had previously intended to carry out a targeted operation against the two Iranian officials, as they had obtained their location information [1] - Pakistan communicated to the U.S. that if these two individuals were eliminated, there would be no dialogue partners left, prompting the U.S. to request Israel to refrain from such actions [1] - The U.S. officials indicated that the deadline for removing the two from the assassination list was "4 to 5 days" [1] Group 2 - Pakistan's Prime Minister Shahbaz expressed readiness to facilitate talks aimed at resolving the current conflict, contingent upon the agreement of both the U.S. and Iran [1]

智通财经APP讯，碧桂园(02007)发布公告，于2026年3月26日，自2025年6月30日起计78个月到期的零息 强制性可转换债券获转换而发行398.56万股。 （原标题：碧桂园(02007)因零息强制性可转换债券获转换而发行398.56万股） ...

Group 1 - The company China Biopharmaceutical (01177.HK) announced a change in its English stock abbreviation from "SINO BIOPHARM" to "SBP GROUP" [1] - The change will take effect on March 31, 2026, at 9:00 AM [1] - The Chinese stock abbreviation will remain unchanged as "中国生物制药" [1]

智通财经APP获悉，里昂发布研报称，中国金茂(00817)连续两年录得盈利，合约销售亦重回增长轨道。 整体而言，该行相信公司正处于清晰的复苏路径，而增持计划亦将管理层与股东的利益绑定，有望推动 估值进一步重估，加上公司的央企背景，可进一步增强投资者信心。目标价由1.32港元上调至1.52港 元，重申"跑赢大市"评级。该行预期，随着高成本库存大致消化，发展物业利润率将触底反弹，预计优 质土地储备将支持利润率保持韧性，带动未来数年盈利增长。 ...

Group 1 - The company reported a revenue of RMB 31.834 billion for the year ending December 31, 2025, representing a year-on-year increase of 10.25% [1] - The profit attributable to the parent company was RMB 2.343 billion, a decrease of 33.04% year-on-year, with basic earnings per share at RMB 0.1302 [1] - The company plans to distribute a final dividend of HKD 0.05 per share [1] Group 2 - The company has entered a period of intensive harvest of innovative products, having received approvals for 16 innovative products over the past three years (2023-2025), including 7 Class 1 innovative drugs [1] - Four innovative products were approved for market launch by NMPA during the reporting period, including Saitanxin, Shenghetu, Putanning, and Anqixin [1] - The revenue from innovative products is expected to reach RMB 15.22 billion in 2025, reflecting a year-on-year growth of 26.2% [1] Group 3 - Research and development (R&D) is the core driving force for the company, which views it as the foundation for sustainable development [2] - The company has established multiple R&D centers in cities such as Shanghai, Nanjing, Beijing, and Guangzhou, creating a diversified innovation technology platform [2] - Total R&D investment for the year ending December 31, 2025, was approximately RMB 6.317 billion, accounting for about 19.8% of the company's revenue, with 92.9% of this amount recognized in the profit and loss statement [2]

智通财经APP讯，中国生物制药(01177)公布， 于香港联合交易所有限公司买卖公司股份的英文股份简 称将由"SINO BIOPHARM"更改为"SBP GROUP"，由2026年3月31日上午九时正起生效。公司中文股份 简称保持不变，仍为"中国生物制药"。 ...

Core Viewpoint - China Biologic Products Holdings (01177.HK) reported a revenue of approximately RMB 31.83 billion for the fiscal year ending December 31, 2025, representing a year-on-year growth of about 10.3% [1] Financial Performance - The sales revenue from innovative products reached approximately RMB 15.22 billion, marking a year-on-year increase of about 26.2%, and accounting for approximately 47.8% of total revenue [1] - The basic profit attributable to equity holders of the parent company was approximately RMB 4.54 billion, reflecting a significant year-on-year growth of 31.4% [1] - Basic earnings per share were reported at 25.22 cents, with the board recommending a final dividend of 5 Hong Kong cents per share [1] Product Approvals - During the reporting period, the company had four innovative products approved by the NMPA, including Setanxin (Kumosili Capsules), Shenghetu® (Zongaitin Tablets), Putanning (Meloxicam Injection® (II)), and Anqixin (Recombinant Human Coagulation Factor VIIa Injection) [1] - Additionally, three Class 1 innovative drugs received NMPA approval for four new indications, including: - Anlotinib combined with Bemarituzumab for first-line treatment of renal cell carcinoma - Anlotinib combined with Paimu Li for first-line treatment of hepatocellular carcinoma - Anlotinib combined with chemotherapy for first-line treatment of soft tissue sarcoma - Paimu Li combined with chemotherapy for first-line treatment of nasopharyngeal carcinoma [1]

Core Viewpoint - The report from Jefferies indicates that Nongfu Spring (09633) has shown significant financial growth in 2025, with revenue increasing by 22.5% to 52.6 billion RMB and net profit rising by 32.7% to 15.9 billion RMB, suggesting strong performance in the second half of 2025 [1][4] Financial Performance - Revenue for 2025 reached 52.6 billion RMB, marking a 22.5% increase year-on-year [1][4] - Net profit for the same year was 15.9 billion RMB, reflecting a year-on-year growth of 32.7% [1][4] - Projections for the second half of 2025 indicate revenue and net profit growth of 30% and 42% respectively [1][4] Future Outlook - Management forecasts double-digit sales growth for 2026, with bottled water sales expected to return to or exceed 2023 levels [1][4] - Due to fluctuations in commodity prices, particularly PET, the company has not provided guidance on profit margins for 2026 [1][4] - As 2026 marks the 30th anniversary of the company, Nongfu Spring plans to implement more promotional strategies to enhance consumer engagement [1][4] Rating and Target Price - Jefferies maintains a "Hold" rating for Nongfu Spring, with a slight increase in the target price from 50 HKD to 50.5 HKD [1][4]

Core Insights - The company reported a significant decline in total revenue for the year ending December 31, 2025, with a decrease from RMB 981 million in 2024 to RMB 574 million, representing a drop of RMB 407 million or 41.5% [1] Revenue Breakdown - The primary reason for the revenue decline was the absence of intellectual property income, which amounted to RMB 678 million in the previous year [1] - Product sales revenue and commercialization rights revenue increased by 90% year-on-year, reaching RMB 574 million [1] Product Performance - Sales revenue for the drug耐立克® (Orelabrutinib) in the Chinese market grew by 81%, rising from RMB 241 million in 2024 to RMB 435 million in 2025 [1] - The drug利生妥® (Lisocabtagene Maraleucel) received approval from China's NMPA in early July 2025 and generated sales revenue of RMB 70.58 million in the last five months of the year [1] Clinical Research - The company is conducting nine Phase III clinical trials globally, with four of them having received approvals from the US FDA and the European EMA [1]

Group 1 - The core viewpoint of the report is that Kuaishou-W (01024) exceeded expectations in its Q4 2025 financial results, with total revenue and adjusted EBIT growing by 12% and 20% year-on-year, reaching 39.6 billion and 6 billion RMB respectively, which is 2% higher than the firm's estimates [1][3] - The annualized revenue for Kuaishou as of December has reached 240 million USD, and it is expected to more than double in 2026, indicating that Kuaishou will become a new growth engine [1][3] - The firm maintains an "outperform" rating on Kuaishou, reflecting confidence in its future performance [1][3]